Sunshine Lake Pharma (HKG:6887) began trading at HK$57.50 on the Hong Kong bourse on Thursday, following its listing by introduction, after completing a merger with Yichang HEC Changjiang Pharmaceutical (HKG:1558).
The vertically integrated drugmaker's listing involved no fundraising.
A total of 112.7 million Sunshine Lake H-shares were admitted to trading on the main board, issued to HEC shareholders at a share exchange ratio of 0.263614 Sunshine Lake share for each HEC H-share cancelled.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.